NEW! Deal Performance Analytics
PharmaDeals Corp-METRx provides vital company metrics that enable comparison of the top 12 Pharmaceutical Companies deal strategies and activities. Covering overall licensing and M&A activity (short and long term), therapeutic focus, plus deal activity relative to R&D spend, this is a key resource for all executives and analysts within biotechnology, pharmaceutical and the financial services sectors.
Updated monthly, PharmaDeals Corp-METRx provides key metrics on the relative strengths and weaknesses of the world’s top 12 pharmaceutical companies. Delivered in a concise and instantly accessible online format, this new publication provides an essential look-up for key facts about how major pharmaceutical companies deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.
Updated monthly, PharmaDeals Corp-METRx provides key metrics on the relative strengths and weaknesses of the world’s top 12 pharmaceutical companies. Delivered in a concise and instantly accessible online format, this new publication provides an essential look-up for key facts about how major pharmaceutical companies deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.
Key Learnings:
- Which of the top 12 is the deal making leader for different therapeutic areas.
- Who is striking the most deals in the short term.
- How do they rank in terms of their long term deal strategies.
- Who are the most acquisitive in the M&A sector
- How are these companies balancing internal and external pipeline filling.
Receive Vital Deal Making Performance Analysis on Top Pharma.
For subscription information, please contact us now on: enquiries@pharmadeals.net
Or telephone +44(0)1865 332700
For subscription information, please contact us now on: enquiries@pharmadeals.net
Or telephone +44(0)1865 332700